Patient Education and Treatment Strategies Implemented at a Pharmacist‐Managed Hepatitis C Virus Clinic
- 1 September 2005
- journal article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 25 (9), 1230-1241
- https://doi.org/10.1592/phco.2005.25.9.1230
Abstract
Hepatitis C virus (HCV) infection is a major public health concern. Approximately 4 million people in the United States have been infected with the virus, and up to 85% of them will develop chronic infection. Chronic HCV infection has often been associated with progression of hepatic fibrosis and, in some cases, cirrhosis and end-stage liver disease. The standard of care is combination therapy with pegylated interferon (peginterferon) alfa plus ribavirin. More than 50% of patients with HCV treated with combination therapy achieve a sustained viral response, defined as undetectable hepatitis C viral RNA 6 months after the end of therapy. Effective patient education and drug therapy management are critical in enabling patients to adhere to the treatment regimen, which is either 24 or 48 weeks long, depending on the virus strain. The drug regimen is associated with several possible adverse events as well as weekly subcutaneous administration (of peginterferon alfa). Frequent monitoring of patients and, often, adjustments in the dosage of one or both components of the therapy are necessary during the treatment course. Strategies used by clinical pharmacists at an HCV clinic are discussed that can facilitate a successful treatment outcome for patients with HCV treated with combination therapy, while enabling them to maintain a reasonable quality of life.This publication has 64 references indexed in Scilit:
- Description of a clinical pharmacist intervention administered to primary care patients with depressionGeneral Hospital Psychiatry, 2004
- Diagnosis, management, and treatment of hepatitis CHepatology, 2004
- Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis CPharmacoEconomics, 2004
- Alpha Interferon Induces Distinct Translational Control Programs To Suppress Hepatitis C Virus RNA ReplicationJournal of Virology, 2003
- Physician‐Pharmacist Comanagement of Hypertension: A Randomized, Comparative TrialPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Peginterferon-??-2a (40kD) Plus RibavirinDrugs, 2003
- Peginterferon-??-2a (40kD)Drugs, 2001
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999
- Epidemiology of hepatitis CHepatology, 1997
- Hepatitis C: The clinical spectrum of diseaseHepatology, 1997